{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:07:48Z","timestamp":1791068868399,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose\/objective<\/jats:title>\n                <jats:p>Currently, there are few prospective data on the tolerability of combining targeted therapies (TT) with radiation therapy (RT). The objective of this prospective study was to assess the feasibility and toxicity of pairing RT with concurrent TT in cancer patients. The aim was to enhance the existing evidence base for the simultaneous administration of targeted substances together with radiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective study enrollment was conducted at a single institution between March 1, 2020, and December 31, 2021, for all patients diagnosed with histologically confirmed cancer who underwent external beam radiotherapy in combination with targeted therapy. The study, known as the \u201ctargeted RT study,\u201d was registered in the German Clinical Trials Register under DRKS00026193. Systematic documentation of the toxicity profiles of different targeted therapies was performed, and the assessment of acute toxicity followed the guidelines of the National Cancer Institute Common Terminology Criteria for Adverse Events Version v5.0.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 334 patients underwent 683 radiation therapy series. During the course of RT, 51 different TT substances were concurrently administered. External beam radiotherapy was employed for various anatomical sites. The combination of RT and concurrent TT administration was generally well tolerated, with no instances of severe acute toxicity observed. The most commonly reported toxicity was fatigue, ranging from mild to moderate Common Terminology Criteria for Adverse Events (CTCAE) \u00b0I-\u00b0III. Other frequently observed toxicities included dermatitis, dyspnea, dysphagia, and dry cough. No toxicity greater than moderate severity was recorded at any point. In only 32 patients (4.7% of evaluated RT series), the concurrent substance administration was discontinued due to side effects. However, these side effects did not exceed mild severity according to CTCAE, suggesting that discontinuation was a precautionary measure. Only one patient receiving Imatinib treatment experienced a severe CTCAE \u00b0III side effect, leading to discontinuation of the concurrent substance due to the sudden occurrence of melaena during RT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, the current study did not demonstrate a significant increase or additional toxicity when combining radiotherapy and concurrent targeted therapy. However, additional research is required to explore the specific toxicity profiles of the various substances that can be utilized in this context.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>DRKS00026193. Date of registration 12\/27\/2022 (retrospectively registered).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-024-02494-7","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:14:43Z","timestamp":1724944483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted RT study: results on early toxicity of targeted therapies and radiotherapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Dinah","family":"Konnerth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Gaasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Sch\u00f6necker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2494_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Reviews Cancer 2012. 2012;12:4. https:\/\/doi.org\/10.1038\/nrc3237.","journal-title":"Nat Reviews Cancer 2012"},{"key":"2494_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3978\/J.ISSN.2078-6891.2013.035","volume":"4","author":"VM Nelson","year":"2013","unstructured":"Nelson VM, Benson AB. Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol. 2013;4:245. https:\/\/doi.org\/10.3978\/J.ISSN.2078-6891.2013.035.","journal-title":"J Gastrointest Oncol"},{"key":"2494_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0099-9","volume":"4","author":"M Yuan","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Therapy 2019. 2019;4:1. https:\/\/doi.org\/10.1038\/s41392-019-0099-9.","journal-title":"Signal Transduct Target Therapy 2019"},{"key":"2494_CR4","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1172\/JCI57152","volume":"121","author":"MJ Higgins","year":"2011","unstructured":"Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Investig. 2011;121:3797\u2013803. https:\/\/doi.org\/10.1172\/JCI57152.","journal-title":"J Clin Investig"},{"key":"2494_CR5","doi-asserted-by":"publisher","unstructured":"Bagnyukova T, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I, Chemotherapy. and signaling. 2010;10:839\u201353. https:\/\/doi.org\/10.4161\/CBT.10.9.13738.","DOI":"10.4161\/CBT.10.9.13738"},{"key":"2494_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/J.CTRO.2020.11.010","volume":"26","author":"C Bosacki","year":"2020","unstructured":"Bosacki C, Bouleftour W, Sotton S, Vallard A, Daguenet E, Ouaz H, et al. CDK 4\/6 inhibitors combined with radiotherapy: a review of literature. Clin Translational Radiation Oncol. 2020;26:79\u201385. https:\/\/doi.org\/10.1016\/J.CTRO.2020.11.010.","journal-title":"Clin Translational Radiation Oncol"},{"key":"2494_CR7","doi-asserted-by":"publisher","unstructured":"Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, et al. Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: a systematic review and meta-analysis. Cancer Treat Rev. 2023;119. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102586.","DOI":"10.1016\/j.ctrv.2023.102586"},{"key":"2494_CR8","unstructured":"Targeted Therapy for Cancer. - NCI n.d. https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies (accessed January 15, 2023)."},{"key":"2494_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","volume":"11","author":"AS Tsao","year":"2016","unstructured":"Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, et al. STATE OF THE ART: CONCISE REVIEW scientific advances in Lung Cancer 2015. J Thorac Oncol. 2016;11:613\u201338. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.012.","journal-title":"J Thorac Oncol"},{"key":"2494_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/S00280-015-2861-1\/METRICS","volume":"76","author":"AM Tsimberidou","year":"2015","unstructured":"Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76:1113\u201332. https:\/\/doi.org\/10.1007\/S00280-015-2861-1\/METRICS.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2494_CR11","doi-asserted-by":"publisher","unstructured":"Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and targeted therapy 2020 5:1 2020;5:1\u201330. https:\/\/doi.org\/10.1038\/s41392-020-0116-z.","DOI":"10.1038\/s41392-020-0116-z"},{"key":"2494_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, Andr\u00e9 F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med 2022. 2022;28:4. https:\/\/doi.org\/10.1038\/s41591-022-01717-2.","journal-title":"Nat Med 2022"},{"key":"2494_CR13","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.3390\/CURRONCOL29100580","volume":"29","author":"CC Mire\u0219tean","year":"2022","unstructured":"Mire\u0219tean CC, Iancu RI, Iancu DT. Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved challenges: Dose, Fractionation, volumes, therapeutic sequence. Curr Oncol (Toronto Ont). 2022;29:7388\u201395. https:\/\/doi.org\/10.3390\/CURRONCOL29100580.","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"2494_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/S00120-022-01966-6","volume":"61","author":"F Eckert","year":"2022","unstructured":"Eckert F. [Multimodal treatment concepts of local radiation therapy with immunotherapy: Rationale for combination therapy and possible clinical treatment strategies]. Urologie (Heidelberg Germany). 2022;61:1324\u201331. https:\/\/doi.org\/10.1007\/S00120-022-01966-6.","journal-title":"Urologie (Heidelberg Germany)"},{"key":"2494_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.5114\/JCB.2021.108601","volume":"13","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Glatzer M, R\u00f6del C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy. 2021;13:458\u201367. https:\/\/doi.org\/10.5114\/JCB.2021.108601.","journal-title":"J Contemp Brachytherapy"},{"key":"2494_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"2494_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMOA2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384:1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMOA2032125.","journal-title":"N Engl J Med"},{"key":"2494_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/S40257-018-0384-3\/FIGURES\/4","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31\u20139. https:\/\/doi.org\/10.1007\/S40257-018-0384-3\/FIGURES\/4.","journal-title":"Am J Clin Dermatol"},{"key":"2494_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/J.CRITREVONC.2013.11.008","volume":"90","author":"MA Pessi","year":"2014","unstructured":"Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, et al. Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol\/Hematol. 2014;90:165\u201379. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2013.11.008.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2494_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/IJD.13371","volume":"56","author":"F Hegedus","year":"2017","unstructured":"Hegedus F, Mathew LM, Schwartz RA. Radiation dermatitis: an overview. Int J Dermatol. 2017;56:909\u201314. https:\/\/doi.org\/10.1111\/IJD.13371.","journal-title":"Int J Dermatol"},{"issue":"Suppl 3","key":"2494_CR21","first-page":"82","volume":"174","author":"J Cla\u00dfen","year":"1998","unstructured":"Cla\u00dfen J, Belka C, Paulsen F, Budach W, Hoffmann W, Bamberg M. Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et Al]. 1998;174(Suppl 3):82\u20134.","journal-title":"Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et Al]"},{"key":"2494_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/JAMAONCOL.2021.6439","volume":"8","author":"MS Anscher","year":"2022","unstructured":"Anscher MS, Arora S, Weinstock C, Amatya A, Bandaru P, Tang C, et al. Association of Radiation Therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database. JAMA Oncol. 2022;8:232\u201340. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.6439.","journal-title":"JAMA Oncol"},{"key":"2494_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.CTRV.2016.11.013","volume":"53","author":"SGC Kroeze","year":"2017","unstructured":"Kroeze SGC, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. 2017;53:25\u201337. https:\/\/doi.org\/10.1016\/J.CTRV.2016.11.013.","journal-title":"Cancer Treat Rev"},{"key":"2494_CR24","doi-asserted-by":"publisher","unstructured":"Kroeze SGC, Fritz C, Schaule J, Blanck O, Kahl KH, Kaul D et al. Continued versus interrupted targeted therapy during Metastasis-Directed Stereotactic Radiotherapy: a retrospective Multi-center Safety and Efficacy Analysis. Cancers 2021;13. https:\/\/doi.org\/10.3390\/CANCERS13194780.","DOI":"10.3390\/CANCERS13194780"},{"key":"2494_CR25","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2017."},{"key":"2494_CR26","unstructured":"LoeScap - Everything. Online PACS n.d. https:\/\/www.loescap.com\/produkt_asena.html (accessed January 15, 2023)."},{"key":"2494_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bjc.1998.599","volume":"78","author":"EMA Smets","year":"1998","unstructured":"Smets EMA, Visser MRM, Willems-Groot AFMN, Garssen B, Oldenburger F, Van Tienhoven G, et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer. 1998;78:899\u2013906. https:\/\/doi.org\/10.1038\/bjc.1998.599.","journal-title":"Br J Cancer"},{"key":"2494_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/bjc.1998.600","volume":"78","author":"EMA Smets","year":"1998","unstructured":"Smets EMA, Visser MRM, Willems-Groot AFMN, Garssen B, Schuster-Uitterhoeve ALJ, De Haes JCJM. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer. 1998;78:907\u201312. https:\/\/doi.org\/10.1038\/bjc.1998.600.","journal-title":"Br J Cancer"},{"key":"2494_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1148\/rg.2019180061","volume":"39","author":"MF Benveniste","year":"2019","unstructured":"Benveniste MF, Gomez D, Carter BW, Betancourt Cuellar SL, Shroff GS, Benveniste APA, et al. Recognizing radiation therapy\u2013 related complications in the chest. Radiographics. 2019;39:344\u201366. https:\/\/doi.org\/10.1148\/rg.2019180061.","journal-title":"Radiographics"},{"key":"2494_CR30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/J.IJROBP.2006.08.058","volume":"66","author":"PG Tsoutsou","year":"2006","unstructured":"Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiation Oncology*Biology*Physics. 2006;66:1281\u201393. https:\/\/doi.org\/10.1016\/J.IJROBP.2006.08.058.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"2494_CR31","first-page":"381","volume":"82","author":"BERKEY FJ","year":"2010","unstructured":"BERKEY FJ. Managing the adverse effects of Radiation Therapy. Am Family Phys. 2010;82:381\u20138.","journal-title":"Am Family Phys"},{"key":"2494_CR32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.jtho.2016.06.002","volume":"11","author":"J Khalifa","year":"2016","unstructured":"Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-Finn C. Brain metastases from NSCLC: Radiation therapy in the era of targeted therapies. J Thorac Oncol. 2016;11:1627\u201343. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.002.","journal-title":"J Thorac Oncol"},{"key":"2494_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","volume":"42","author":"JA Wargo","year":"2015","unstructured":"Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune effects of Chemorapy, Radiation, and targeted rapy and opportunities for Combination with Immunorapy. Semin Oncol. 2015;42:601\u201316. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.05.007.","journal-title":"Semin Oncol"},{"key":"2494_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3978\/j.issn.2218-6751.2015.10.05","volume":"4","author":"CB Simone","year":"2015","unstructured":"Simone CB, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Translational Lung Cancer Res. 2015;4:545\u201352. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.10.05.","journal-title":"Translational Lung Cancer Res"},{"key":"2494_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","volume":"39","author":"H Wang","year":"2018","unstructured":"Wang H, Mu X, He H, Zhang XD. Cancer Radiosensitizers. Trends Pharmacol Sci. 2018;39:24\u201348. https:\/\/doi.org\/10.1016\/j.tips.2017.11.003.","journal-title":"Trends Pharmacol Sci"},{"key":"2494_CR36","doi-asserted-by":"publisher","unstructured":"Kareliotis G, Tremi I, Kaitatzi M, Drakaki E, Serafetinides AA, Makropoulou M et al. Combined radiation strategies for novel and enhanced cancer treatment. Int J Radiat Biol 2020:1087\u2013103. https:\/\/doi.org\/10.1080\/09553002.2020.1787544.","DOI":"10.1080\/09553002.2020.1787544"},{"key":"2494_CR37","first-page":"311","volume":"77","author":"GERBER DE","year":"2008","unstructured":"GERBER DE. Targeted therapies: a New Generation of Cancer treatments. Am Family Phys. 2008;77:311\u20139.","journal-title":"Am Family Phys"},{"key":"2494_CR38","doi-asserted-by":"publisher","unstructured":"Xing DT, Khor R, Gan H, Wada M, Ermongkonchai T, Ng SP. Recent research on combination of Radiotherapy with targeted therapy or immunotherapy in Head and Neck Squamous Cell Carcinoma: a review for Radiation oncologists. Cancers 2021. Page 5716 2021;13:13:5716. https:\/\/doi.org\/10.3390\/CANCERS13225716.","DOI":"10.3390\/CANCERS13225716"},{"key":"2494_CR39","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24:e121\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(22)00752-5.","journal-title":"Lancet Oncol"},{"key":"2494_CR40","unstructured":"Strahlenschutzkommission. Kombinationswirkungen Strahlentherapie\/medikament\u00f6se Tumortherapie n.d."},{"key":"2494_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10620-005-1279-8","volume":"50","author":"II El Hajj","year":"2005","unstructured":"El Hajj II, Chehal A, El Saghir NS. Recurrent GI bleeding and surgery following the initial response to Imatinib Therapy in GIST of the stomach. Dig Dis Sci. 2005;50:65\u20139. https:\/\/doi.org\/10.1007\/s10620-005-1279-8.","journal-title":"Dig Dis Sci"},{"key":"2494_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/07357900500449678","volume":"24","author":"T Rabinowitz","year":"2006","unstructured":"Rabinowitz T, Peirson R. Nothing is wrong, doctor: understanding and managing denial in patients with cancer. Cancer Invest. 2006;24:68\u201376. https:\/\/doi.org\/10.1080\/07357900500449678.","journal-title":"Cancer Invest"},{"key":"2494_CR43","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/J.IJROBP.2020.04.040","volume":"107","author":"AT Fairchild","year":"2020","unstructured":"Fairchild AT, Tanksley JP, Tenenbaum JD, Palta M, Hong JC. Interrater reliability in toxicity identification: limitations of current standards. Int J Radiation Oncology*Biology*Physics. 2020;107:996\u20131000. https:\/\/doi.org\/10.1016\/J.IJROBP.2020.04.040.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"2494_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/096228020000900505","volume":"9","author":"JC Nelson","year":"2000","unstructured":"Nelson JC, Pepe MS. Statistical description of interrater variability in ordinal ratings. Http:\/\/DxDoiOrg\/101177\/096228020000900505. 2000;9:475\u201396. https:\/\/doi.org\/10.1177\/096228020000900505.","journal-title":"https:\/\/doi.org\/10.1177\/096228020000900505"},{"key":"2494_CR45","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/J.1365-2753.2011.01705.X","volume":"18","author":"S Tuijn","year":"2012","unstructured":"Tuijn S, Janssens F, Robben P, Van Den Bergh H. Reducing interrater variability and improving health care: a meta-analytical review. J Eval Clin Pract. 2012;18:887\u201395. https:\/\/doi.org\/10.1111\/J.1365-2753.2011.01705.X.","journal-title":"J Eval Clin Pract"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02494-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:16:29Z","timestamp":1724944589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02494-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2494"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02494-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"13 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the local ethics committee: \u201cEthikkommission bei der LMU M\u00fcnchen\u201d, project number 19\u2013470.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}